Cowden Syndrome Companies

Amgen announces Phase 3 trial results for AMG 986, a potential targeted therapy for Cowden Syndrome promising results indicate the potential for AMG 986 to control cell growth and prevent tumor formation in individuals with Cowden Syndrome.

Spectrum Pharmaceuticals receives Orphan Drug Designation from the FDA for poziotinib for the treatment of Cowden Syndrome designation grants marketing exclusivity and potential development pathway support for poziotinib, providing hope for future treatment options.

Foundation Medicine launches FoundationOne CDx for comprehensive cancer and hereditary disease gene testing advanced test panel includes genes associated with Cowden Syndrome, allowing for more precise diagnosis and treatment guidance.

List of Cowden Syndrome Key Companies in the Market

• Novartis AG (Switzerland)


• GlaxoSmithKline Plc. (U.K.)


• Bayer AG (Germany)


• Amgen Inc. (U.S.)


• Eli Lilly and Company (U.S.)


• AstraZeneca Plc. (U.K.)


• Bristol-Myers Squibb Company (U.S.)


• Sanofi (France)


• AbbVie Inc. (U.S.)


• Spectrum Pharmaceuticals Inc. (U.S.)


• Takeda Pharmaceuticals (Japan)


• Pfizer Inc. (U.S.)


• Merck & Co. Inc. (U.S.)


• Hoffmann-La Roche Ltd. (Switzerland)


• Janssen Biotech Inc. (U.S.)


• Immunomedics (U.S.)


• and Oncomed Pharmaceuticals (U.S.)